布地奈德混悬液联合肺泡表面活性物质注射治疗新生儿呼吸窘迫综合征的疗效及其对血清铁蛋白和PAI-1表达的影响。
Therapeutic efficacy of budesonide suspension combined with poractant alfa injection for neonatal respiratory distress syndrome and its effect on serum ferritin and PAI-1 expressions.
作者信息
Xu Yunbo, Chen Wenchao
机构信息
Yunbo Xu Department of Neonatal Pediatrics, Huangshi Maternity and Children's Health Hospital, Affiliated Maternity and Children's Health Hospital of Hubei Polytechnic University, Huangshi Key Laboratory of Birth Defects Prevention, Huangshi 435000, China.
Wenchao Chen Department of Neonatal Pediatrics, Huangshi Maternity and Children's Health Hospital, Affiliated Maternity and Children's Health Hospital of Hubei Polytechnic University, Huangshi Key Laboratory of Birth Defects Prevention, Huangshi 435000, China.
出版信息
Pak J Med Sci. 2025 May;41(5):1488-1493. doi: 10.12669/pjms.41.5.10496.
OBJECTIVE
To investigate the therapeutic efficacy of budesonide suspension combined with poractant alfa injection for neonatal respiratory distress syndrome (NRDS) and the underlying action mechanisms.
METHODS
Sixty NRDS patients treated in Huangshi Maternity and Children's Health Hospital from May 2021 to May 2023 were enrolled and were divided into control and observation groups, which were treated with poractant alfa injection and budesonide suspension combined with poractant alfa injection, respectively.
RESULTS
After 72 hours of treatment, the total efficacy in observation group was significantly higher than control group. Compared with control treatment, in observation group the partial pressure of oxygen was significantly increased, the partial pressure of carbon dioxide, peak inspiratory pressure, respiratory rate, fraction of inspired oxygen and serum tumor necrosis factor-α, interleukin-6, high-sensitivity C-reactive protein, serum ferritin and plasminogen activator inhibitor-1 levels were significantly decreased.
CONCLUSION
Compared with poractant alfa injection, budesonide suspension combined with poractant alfa injection is more effective in treatment of NRDS. The action mechanisms may be related to its further reduction of inflammatory response and inhibition of serum ferritin and plasminogen activator inhibitor-1 expressions.
目的
探讨布地奈德混悬液联合肺泡表面活性物质注射用牛肺表面活性剂治疗新生儿呼吸窘迫综合征（NRDS）的疗效及潜在作用机制。
方法
选取2021年5月至2023年5月在黄石市妇幼保健院治疗的60例NRDS患者，分为对照组和观察组，分别采用注射用牛肺表面活性剂、布地奈德混悬液联合注射用牛肺表面活性剂治疗。
结果
治疗72小时后，观察组总有效率显著高于对照组。与对照治疗相比，观察组氧分压显著升高，二氧化碳分压、吸气峰压、呼吸频率、吸入氧分数及血清肿瘤坏死因子-α、白细胞介素-6、高敏C反应蛋白、血清铁蛋白和纤溶酶原激活物抑制剂-1水平显著降低。
结论
与注射用牛肺表面活性剂相比，布地奈德混悬液联合注射用牛肺表面活性剂治疗NRDS更有效。其作用机制可能与其进一步减轻炎症反应及抑制血清铁蛋白和纤溶酶原激活物抑制剂-1表达有关。
Zotero 插件